What Does the Evidence Show About Tysabri and PML Symptoms?
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
Legacy of General Health Information and Occupational Exposure
If you or a loved one is taking Tysabri, you may have heard about the rare brain infection PML and its early symptoms. The medical community has long relied on cumulative evidence from clinical trials and post-market surveillance to understand how this risk evolves over time. This page summarizes what current research and FDA reports can and cannot tell us about recognizing PML symptoms.
Medical Background and Clinical Presentation of PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Early recognition is essential because Tysabri must be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic link between Tysabri and PML involves reduced immune surveillance in the brain. By blocking lymphocyte trafficking across the blood-brain barrier, Tysabri diminishes the ability of the immune system to control JC virus replication. This allows the virus to infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is further elevated in patients with prior immunosuppressant use, which may compound immune impairment.
Settlement-Related Considerations for Affected Patients
For patients in Washington who have developed PML after Tysabri treatment, settlement considerations may include the timeline between exposure and documented harm. PML can occur after varying durations of Tysabri therapy, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The statute of limitations for filing a claim in Washington generally requires that a lawsuit be brought within a certain period from the date the injury was discovered or should have been discovered. For medical product liability cases, this typically means the clock starts when the patient knew or reasonably should have known that Tysabri caused the PML. Given the severity of PML, early diagnosis is critical, but the neurological deficits may delay recognition of the link. Patients and their families should consult with legal counsel promptly to assess their specific circumstances and ensure compliance with Washington's filing deadlines.
Tysabri-associated PML is a devastating condition with well-characterized risk factors and a clear mechanistic basis. The FDA-mandated warnings and TOUCH program aim to mitigate risk, but affected patients in Washington must be aware of the statute of limitations for pursuing settlement claims. Given the complexity of medical and legal issues, individuals who have developed PML after Tysabri treatment should seek both specialized medical care and experienced legal counsel to protect their rights.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Washington?
In Washington, the statute of limitations for medical product liability claims generally requires filing within a certain period from when the injury was discovered or should have been discovered. For Tysabri-related PML, this typically starts when the patient knew or reasonably should have known that Tysabri caused the PML. Given the severity and delayed recognition of PML, it is crucial to consult with legal counsel promptly to ensure compliance with Washington's filing deadlines.
What are the risk factors for developing PML from Tysabri?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.